var data={"title":"Cefuroxime: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefuroxime: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5849?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefuroxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefuroxime: Patient drug information&quot;</a> and <a href=\"topic.htm?path=cefuroxime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefuroxime: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148304\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ceftin;</li>\n      <li>Zinacef in Sterile Water [DSC];</li>\n      <li>Zinacef [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148305\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cefuroxime;</li>\n      <li>Auro-Cefuroxime;</li>\n      <li>Ceftin;</li>\n      <li>Cefuroxime For Injection;</li>\n      <li>Cefuroxime For Injection, USP;</li>\n      <li>PRO-Cefuroxime;</li>\n      <li>ratio-Cefuroxime</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148353\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Second Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148308\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.  All oral doses listed are for tablet formulation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute bacterial maxillary sinusitis:</b> Oral: 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Bone and joint infections:</b> IM, IV: 1.5 g every 8 hours (adjunctive surgical intervention may be necessary); upon completion of parenteral therapy follow with oral antibiotic therapy if indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial exacerbations of chronic bronchitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 to 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 500 to 750 mg every 8 hours (complete therapy with oral dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholecystitis, mild to moderate (off-label):</b> IV: 1.5 g every 8 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired, mild to moderate (in combination with metronidazole): (off-label): </b> IV: 1.5 g every 8 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (early):</b> Oral: 500 mg twice daily for 20 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis:</b> Oral: 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Cefuroxime is considered an <b>alternate</b> therapy for CAP in adults caused by <i>Streptococcus pneumoniae</i> (with MICs &lt;2 mcg/mL for penicillin); may also be used as outpatient empiric therapy in combination with a macrolide (preferred) or doxycycline (IDSA [Mandell 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (off-label route in US): 500 mg twice daily for a minimum of 5 days (patients should be afebrile for &ge;48 hours and clinically stable before discontinuing therapy) (IDSA [Mandell 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: IM, IV: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: IV: 1.5 g every 8 hours. Note: This higher dose should be considered in hospitalized patients, especially if bacteremic (Caballero-Granado 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe or complicated infections:</b> IV: 1.5 g every 8 hours (up to 1.5 g every 6 hours in life-threatening infections)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin/skin structure infection, uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 to 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 1.5 g 30 minutes to 1 hour prior to procedure (if procedure is prolonged can give 750 mg every 8 hours IV or IM)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Open heart:</i> IV: 1.5 g every 12 hours for a total of 4 doses starting at anesthesia induction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendation:</i> 1.5 g within 60 minutes prior to surgical incision. Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection, uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 mg twice daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, IM: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal) (off-label use) (IDSA [Stevens 2014]):</b> Oral: 500 mg twice daily in combination with clindamycin or metronidazole for anaerobic coverage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148329\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cefuroxime-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cefuroxime: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Children &ge;1 year:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical (perioperative) prophylaxis:</b>  IV:  50 mg/kg within 60 minutes prior to surgical incision (maximum dose: 1,500 mg). Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &ge;3 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute bacterial maxillary sinusitis, acute otitis media: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Suspension: 30 mg/kg/day in 2 divided doses for 10 days (maximum dose: 1,000 mg/day); tablet: 250 mg twice daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 75 to 150 mg/kg/day divided every 8 hours (maximum dose: 6 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone and joint infection: </b>IM, IV: 50 mg/kg/dose every 8 hours; maximum single dose: 1,500 mg. Upon completion of parenteral therapy follow with oral antibiotic therapy if indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Suspension: 20 mg/kg/day (maximum: 500 mg/day) in 2 divided doses for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 75 to 150 mg/kg day divided every 8 hours (maximum: 6 g/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infection (impetigo):</b> Oral: Suspension: 30 mg/kg/day in 2 divided doses for 10 days (maximum dose: 1,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, uncomplicated (off-label dosing):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &ge;2 months to 2 years: Oral: 20 to 30 mg/kg/day divided twice daily for 7 to 14 days (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years: Moderate to severe disease (possible pyelonephritis): Oral: 20 to 30 mg/kg/day divided twice daily (maximum dose: 1,000 mg/day) (Bradley 2012; <i>Red Book</i> [AAP 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute bacterial exacerbations of chronic bronchitis: </b>Oral: 250 to 500 mg every 12 hours for 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute bacterial maxillary sinusitis: </b>Oral: 250 mg twice daily for 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone and joint infection:</b> IM, IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease (early):</b> Oral: 500 mg twice daily for 20 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/tonsillitis: </b>Oral: 250 mg every 12 hours for 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin/skin structure infection, uncomplicated: </b>Oral: 250 to 500 mg every 12 hours for 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, uncomplicated: </b>Oral: 250 mg twice daily for 7 to 10 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148309\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148310\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to &lt;30 mL/minute: Administer recommended dose based on indication every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer recommended dose based on indication every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring intermittent hemodialysis (IHD): Additional recommended dose based on indication should be given at the end of each dialysis session.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been reported in the literature (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 30 mg/kg/day divided every 12 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute/1.73 m<sup>2</sup>: 15 mg/kg/dose every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 15 mg/kg/dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Dialyzable: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;20 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 20 mL/minute: Administer recommended dose based on indication every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer recommended dose based on indication every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer additional recommended dose based on indication at the end of dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;3 months, Children, and Adolescents: Administer recommended dose based on indication but decrease frequency similar to the adult recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing (Aronoff 2007):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Administer full dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: 25 to 50 mg/kg dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: 1 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: 25 to 50 mg/kg every 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682556\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148279\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef in Sterile Water: 1.5 g (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravitreal, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL in NaCl 0.9% (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef: 750 mg (1 ea [DSC]); 1.5 g (1 ea [DSC]); 7.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 750 mg (1 ea); 1.5 g (1 ea); 7.5 g (1 ea); 75 g (1 ea [DSC]); 225 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef: 750 mg (1 ea [DSC]); 1.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 750 mg (1 ea [DSC]); 1.5 g (1 ea); 7.5 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as axetil [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceftin: 125 mg/5 mL (100 mL); 250 mg/5 mL (50 mL [DSC], 100 mL) [contains aspartame; tutti-frutti flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as axetil [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceftin: 250 mg [DSC], 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148263\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148283\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension: Administer with food. Shake well before use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral tablet: May administer with or without food. Swallow tablet whole (crushed tablet has strong, persistent, bitter taste).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Inject deep IM into large muscle mass. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Inject direct IV over 3 to 5 minutes. Infuse intermittent infusion over 15 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148282\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial maxillary sinusitis (tablets and oral suspension only): </b> Treatment of mild to moderate acute bacterial maxillary sinusitis in adults and pediatric patients &ge;3 months caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i> (non-beta-lactamase-producing strains only).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Effectiveness for sinus infections caused by beta-lactamase&ndash;producing <i>H. influenzae</i> or <i>M. catarrhalis</i> in patients with acute bacterial maxillary sinusitis has not been established. <b>Note</b>: According to the IDSA guidelines for acute bacterial rhinosinusitis, cefuroxime is no longer recommended as monotherapy for initial empiric treatment (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial exacerbations of chronic bronchitis (tablets only): </b> Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in adults and adolescents &ge;13 years caused by <i>S. pneumoniae</i>, <i>H. influenzae</i> (beta-lactamase negative strains), or <i>Haemophilus parainfluenzae</i> (beta-lactamase negative strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute otitis media (tablets and oral suspension only):</b> Treatment of pediatric patients &ge;3 months with acute bacterial otitis media caused by <i>S. pneumoniae</i>, <i>H. influenzae</i> (including beta-lactamase-producing strains), <i>Moraxella catarrhalis</i> (including beta-lactamase-producing strains), or <i>Streptococcus pyogenes.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone and joint infections (injection only):</b> Treatment of bone and joint infections caused by <i>Staphylococcus aureus</i> (penicillinase- and non-penicillinase-producing strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections (injection only):</b> Treatment of lower respiratory tract infections, including pneumonia, caused by <i>S. pneumoniae</i>, <i>H. influenzae</i> (including ampicillin-resistant strains), <i>Klebsiella</i> spp., <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>S. pyogenes</i>, and <i>Escherichia coli</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (early) (tablets only):</b> Treatment of adults and adolescents &ge;13 years with early Lyme disease caused by <i>Borrelia burgdorferi</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis/tonsillitis (tablets and oral suspension only):</b> Treatment of mild to moderate pharyngitis/tonsillitis caused by <i>S. pyogenes</i> in adults and pediatric patients &ge;3 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: The efficacy in the prevention of rheumatic fever has not been established in clinical trials. Efficacy in the treatment of penicillin-resistant strains of <i>S. pyogenes</i> has not been demonstrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septicemia (injection only):</b> Treatment of septicemia caused by <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>S. pneumoniae</i>, <i>E. coli</i>, <i>H. influenzae</i> (including ampicillin-resistant strains), and <i>Klebsiella</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infection (impetigo) (oral suspension only):</b> Treatment of pediatric patients 3 months to 12 years of age with skin or skin structure infections (impetigo) caused by <i>S. aureus</i> (including beta-lactamase-producing strains) or <i>S. pyogenes</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infection (injection; tablets [uncomplicated infections only]):</b> Treatment of adults and pediatric patients &gt;3 months with skin and skin-structure infections (including impetigo) caused by <i>S. aureus</i> (penicillinase- and non-penicillinase-producing strains), <i>S. pyogenes</i>, <i>E. coli</i>, <i>Klebsiella</i> spp., and <i>Enterobacter</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (injection only):</b> Prophylaxis of infection in patients undergoing surgical procedures (eg, vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections (tablets and injection only):</b> Treatment of adults and pediatric patients &gt;3 months with urinary tract infections caused by <i>E. coli</i> and <i>Klebsiella</i> spp.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28575415\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bite wounds (animal); Intra-abdominal Infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148361\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefuroxime may be confused with cefotaxime, cefprozil, deferoxamine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ceftin may be confused with Cefzil, Cipro</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zinacef may be confused with Zithromax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ceftin [US, Canada] may be confused with Cefiton brand name for cefixime [Portugal]; Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148270\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Gastrointestinal: Diarrhea (4% to 11%, duration dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Local thrombophlebitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaper rash (children 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea and vomiting (3% to 7%), unpleasant taste (children 5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginitis (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hematocrit (&le;10%), decreased hemoglobin (&le;10%), eosinophilia (1% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum transaminases (2% to 4%), increased serum alkaline phosphatase (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Jarisch-Herxheimer reaction (6%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Abdominal pain, anaphylaxis, angioedema, anorexia, arthralgia, brain disease, candidiasis, chest pain, chest tightness, chills, cholestasis, <i>Clostridium difficile</i> associated diarrhea, colitis, cough, decreased creatinine clearance, dizziness, drowsiness, drug fever, dyspepsia, dyspnea, dysuria, erythema, erythema multiforme, fever, flatulence, gastrointestinal hemorrhage, gastrointestinal infection, glossitis, headache, hearing loss, hemolytic anemia, hepatitis, hyperactivity, hyperbilirubinemia, hypersensitivity, hypersensitivity angiitis, increased blood urea nitrogen, increased liver enzymes, increased serum creatinine, increased thirst, interstitial nephritis, irritability, jaundice, joint swelling, leukopenia, muscle cramps, muscle rigidity, muscle spasm (neck), neutropenia, oral mucosa ulcer, pancytopenia, positive direct Coombs test, prolonged prothrombin time, pruritus, pseudomembranous colitis, renal insufficiency, renal pain, seizure, serum sickness-like reaction, sialorrhea, sinusitis, skin rash, Stevens-Johnson syndrome, stomach cramps, tachycardia, thrombocytopenia (rare), toxic epidermal necrolysis, trismus, upper respiratory tract infection, urethral bleeding, urethral pain, urinary tract infection, urticaria, vaginal discharge, vaginal irritation, viral infection, vulvovaginal candidiasis, vulvovaginal pruritus </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148286\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefuroxime, any component of the formulation, or other beta-lactam antibacterial drugs (eg, penicillins and cephalosporins)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148267\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam drugs. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or other allergen hypersensitivity. Use caution if given to a patient with a penicillin or other beta-lactam allergy because cross sensitivity among beta-lactam antibacterial drugs has been established. If an allergic reaction occurs, discontinue and institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; cephalosporins have been associated with seizure activity, particularly in patients with renal impairment not receiving dose adjustments. Discontinue if seizures occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suspension/tablet bioequivalence: Tablets and oral suspension are not bioequivalent; do not substitute on a mg-per-mg basis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablets:  Should not be crushed or chewed due to a strong, persistent bitter taste.  Patients unable to swallow whole tablets should be prescribed the oral suspension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298999\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9230&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Cefuroxime. Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the absorption of Cefuroxime.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148300\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Bioavailability is increased with food; cefuroxime serum levels may be increased if taken with food or dairy products. Clinical and bacteriologic responses were independent of food intake in clinical trials. Management: Administer tablet without regard to meals; suspension must be administered with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148275\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5193889\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Cefuroxime crosses the placenta and reaches the cord serum and amniotic fluid. Placental transfer is decreased in the presence of oligohydramnios. Several studies have failed to identify an increased teratogenic risk to the fetus following maternal cefuroxime use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">During pregnancy, mean plasma concentrations of cefuroxime are 50% lower, the AUC is 25% lower, and the plasma half-life is shorter than nonpregnant values. At term, plasma half-life is similar to nonpregnant values and peak maternal concentrations after IM administration are slightly decreased. Pregnancy does not alter the volume of distribution. Cefuroxime is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148289\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime IV is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148290\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain phenylalanine and/or sodium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Should be taken with food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148277\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Monitor prothrombin time in patients at risk of prolongation during cephalosporin therapy (nutritionally-deficient, prolonged treatment, renal or hepatic disease). Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148266\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148285\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral tablet: Increases with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to body tissues and fluids including bronchial secretions, synovial and pericardial fluid, kidneys, heart, liver, bone and bile; crosses blood-brain barrier; therapeutic concentrations achieved in CSF even when meninges are not inflamed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 33% to 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Cefuroxime axetil (oral) is hydrolyzed in the intestinal mucosa and blood to cefuroxime </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Tablet: Fasting: 37%; Following food: 52%; cefuroxime axetil suspension is less bioavailable than the tablet (91% of the AUC for tablets)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premature neonates: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;3 days: Median: 5.8 hours (de Louvois 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &ge;8 days: Median: 1.6-3.8 hours (de Louvois 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: 1.4-1.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~1 to 2 hours; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: ~15 to 60 minutes; IV: 2 to 3 minutes; Oral: Children: ~3 to 4 hours; Adults: ~2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (66% to 100% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148288\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cefuroxime Sodium-NaCl (PF) Intravitreal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL 0.9% (1 mL): $41.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefuroxime Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 g (1): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 g (1): $23.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (1): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefuroxime Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 g (1): $6.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Ceftin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $174.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $296.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cefuroxime Axetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (20): $87.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $160.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148291\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actixim (VN);</li>\n      <li>Adrox (BD);</li>\n      <li>Alporin (KR);</li>\n      <li>Altacef (PH);</li>\n      <li>Altamax (PH);</li>\n      <li>Anbacim (ID);</li>\n      <li>Aprok (IE);</li>\n      <li>Aprokam (GB);</li>\n      <li>Axet (PH);</li>\n      <li>Axetine (CN, NZ, PH, SG);</li>\n      <li>Axim (BD, HK);</li>\n      <li>Axurocef (TW);</li>\n      <li>Bacticef (IN);</li>\n      <li>C-Tri T (TH);</li>\n      <li>Carvixime (PH);</li>\n      <li>Cef2 (TZ);</li>\n      <li>Cefabiot (MX);</li>\n      <li>Cefasun (IN);</li>\n      <li>Cefero (LK);</li>\n      <li>Ceflour (MY);</li>\n      <li>Cefmono (PH);</li>\n      <li>Cefosan (PH);</li>\n      <li>Ceftil (KR);</li>\n      <li>Cefudura (DE);</li>\n      <li>Cefuhexal (DE);</li>\n      <li>Cefumax (LB, PH);</li>\n      <li>Cefuracet (MX);</li>\n      <li>Cefurax (DE);</li>\n      <li>Cefuro-Puren (DE);</li>\n      <li>Cefurox (TH);</li>\n      <li>Cefurox-wolff (DE);</li>\n      <li>Cefutil (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Cefutin (KR);</li>\n      <li>Cefuxime (HK, KR);</li>\n      <li>Cefxin (SG);</li>\n      <li>Cefzime (PH);</li>\n      <li>Celocid (ID);</li>\n      <li>Ceprosim (KR);</li>\n      <li>Cerox A (BD);</li>\n      <li>Ceroxim (IL, ZA);</li>\n      <li>Cethixim (ID);</li>\n      <li>Cetil (ET, IN, PE);</li>\n      <li>Cetoxil (MX);</li>\n      <li>Cexil (KR);</li>\n      <li>Cexim (HU);</li>\n      <li>CMaxid (HK);</li>\n      <li>Cortum (PH);</li>\n      <li>Curocef (AT, CL);</li>\n      <li>Curoxime (PT);</li>\n      <li>Daliroxim (LK);</li>\n      <li>Daroxime (LB, QA);</li>\n      <li>Deltrox (AR);</li>\n      <li>Efox (HR);</li>\n      <li>Efurox (MY);</li>\n      <li>Elobact (DE);</li>\n      <li>Eroxmit (PH);</li>\n      <li>Famicef (BD);</li>\n      <li>Farmacef (TH);</li>\n      <li>Fornax (PE);</li>\n      <li>Froxime (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Furacam (EC);</li>\n      <li>Furobioxin (MX);</li>\n      <li>Furoxim (PH);</li>\n      <li>Furoxime (TH);</li>\n      <li>Glanax (VN);</li>\n      <li>Gomcef (KR);</li>\n      <li>Jectocef (PH);</li>\n      <li>Keef-250 (PH);</li>\n      <li>Kefezy (PH);</li>\n      <li>Kefrox (LK);</li>\n      <li>Kefstar (PH);</li>\n      <li>Kefurox (LU);</li>\n      <li>Ketocef (HR);</li>\n      <li>Kimatsef (UA);</li>\n      <li>Magnaspor (TH);</li>\n      <li>Maxil (JO, QA);</li>\n      <li>Medaxetine (VN);</li>\n      <li>Medxime (PH);</li>\n      <li>Milcef (LK);</li>\n      <li>Neurox-250 (TH);</li>\n      <li>Novador (MX);</li>\n      <li>Novocef (HR);</li>\n      <li>Olcef (KR);</li>\n      <li>Orapen (ZW);</li>\n      <li>Oraxim (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Oxtercid (ID);</li>\n      <li>Profurex (PH);</li>\n      <li>Rucef (PH);</li>\n      <li>Sefuxim (HK);</li>\n      <li>Sharox-500 (ID);</li>\n      <li>Shincef (KR);</li>\n      <li>Situroxime (ID);</li>\n      <li>Teikeden (HK);</li>\n      <li>Unoximed (PH);</li>\n      <li>Vekfazolin (GR);</li>\n      <li>Vexuro (LK);</li>\n      <li>Xorim (LB, QA);</li>\n      <li>Xorimax (HK, LB, MY, PH, QA, SG);</li>\n      <li>Xorufec (MX);</li>\n      <li>Yokel (UA);</li>\n      <li>Zamur (CR, DO, GT, HN, NI, PA, QA, SV, TT);</li>\n      <li>Zegen (PH);</li>\n      <li>Zenon (QA);</li>\n      <li>Zetnil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Zilisten (MT);</li>\n      <li>Zinacef (AE, BB, BE, BG, BH, CH, CN, CO, CY, CZ, DK, EE, ES, ET, FI, GB, GR, HU, IE, IS, JO, KW, LB, LK, LT, LU, MT, NL, NO, NZ, PH, PL, PT, QA, RU, SA, SE, SK, TR, VN, ZW);</li>\n      <li>Zinat (CH);</li>\n      <li>Zincef (KR);</li>\n      <li>Zinnat (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, RO, SA, SC, SD, SG, SK, SL, SN, SR, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Zocef (TH, TZ);</li>\n      <li>Zoref (PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 19th ed. Philadelphia, PA: Lippincott Williams amp Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broekhuysen J, Deger F, Douchamps J, et al, &ldquo;Pharmacokinetic Study of Cefuroxime in the Elderly,&rdquo; <i>Br J Clin Pharmacol</i>, 1981, 21(6):801-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/7340882/pubmed\" target=\"_blank\" id=\"7340882\">7340882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8723497\"></a>Caballero-Granado FJ, Palomino-Nic&aacute;s J, Pach&oacute;n J, Garc&iacute;a-Curiel A. Letters to the editor cefuroxime efficacy in treatment of bacteremic pneumonia due to penicillin- resistant and cefuroxime-resistant streptococcus pneumoniae. <i>Antimicrob Agents Chemother</i>. 1996;40(5):1325-1326.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/8723497/pubmed\" target=\"_blank\" id=\"8723497\">8723497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceftin (cefuroxime) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefuroxime and dextrose (duplex container) [prescribing information]. Bethlehem, PA: B. Braun Medical; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Louvois J, Mulhall A, and Hurley R, &ldquo;Cefuroxime in the Treatment of Neonates,&rdquo; <i>Arch Dis Child</i>, 1982, 57(1):59-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/7065695/pubmed\" target=\"_blank\" id=\"7065695\">7065695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douglas JG, Bax RP, and Munro JF, &ldquo;The Pharmacokinetics of Cefuroxime in the Elderly,&rdquo; <i>J Antimicrob Chemother</i>, 1980, 6(4):543-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/7430016/pubmed\" target=\"_blank\" id=\"7430016\">7430016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentry LO, Zeluff BJ, and Cooley DA, &ldquo;Antibiotic Prophylaxis in Open-Heart Surgery: A Comparison of Cefamandole, Cefuroxime, and Cefazolin,&rdquo; <i>Ann Thorac Surg</i>, 1988, 46(2):167-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/3401076/pubmed\" target=\"_blank\" id=\"3401076\">3401076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gooch WM 3rd, Blair E, Puopolo A, et al, &ldquo;Effectiveness of Five Days of Therapy With Cefuroxime Axetil Suspension for Treatment of Acute Otitis Media,&rdquo; <i>Pediatr Infect Dis J</i>, 1996, 15(2):157-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/8822290/pubmed\" target=\"_blank\" id=\"8822290\">8822290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44 Suppl 2:S27-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JD, &ldquo;Cefuroxime: A Cephalosporin With Unique Applicability to Pediatric Practice,&rdquo; <i>Pediatr Infect Dis</i>, 1983, 2(5):394-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/6356062/pubmed\" target=\"_blank\" id=\"6356062\">6356062</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peterson CD, Lake KD, Arom KV, et al, &ldquo;Antibiotic Prophylaxis in Open-Heart Surgery Patients: Comparison of Cefamandole and Cefuroxime,&rdquo; <i>Drug Intell Clin Pharm</i>, 1987, 21(9):728-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/3498617/pubmed\" target=\"_blank\" id=\"3498617\">3498617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months [published online ahead of print August 28, 2011].<i>Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefuroxime-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinacef (cefuroxime) [prescribing information]. Cary, NC: Covis; October 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9230 Version 227.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F148304\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F148305\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F148353\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F148308\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F148329\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F148309\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F148310\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682556\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148279\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F148263\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F148283\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F148282\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28575415\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F148361\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148270\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F148286\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148267\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298999\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F148300\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148275\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5193889\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F148289\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F148290\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F148277\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148266\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F148285\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F148288\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F148291\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9230|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefuroxime-patient-drug-information\" class=\"drug drug_patient\">Cefuroxime: Patient drug information</a></li><li><a href=\"topic.htm?path=cefuroxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefuroxime: Pediatric drug information</a></li></ul></div></div>","javascript":null}